| Printable Copy |
 |
| Printable Copy |
|
BMC Infect Dis. 2016 Apr 30;16(1):190. doi: 10.1186/s12879-016-1499-x.
Seroprevalence of antibodies to measles mumps and rubella and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
Chaiwarith R1 Praparattanapan J2 Nuket K2 Kotarathitithum W2 Supparatpinyo K23.
Abstract
BACKGROUND:
After the global implementation of national immunization programs for prevention of measles mumps and rubella (MMR) the prevalences of protective antibodies to these viruses are high in general population. However there are limited data among human immunodeficiency virus (HIV)-1 infected individuals. This study aimed to determine the seroprevalence of antibodies to these viruses and the serologic responses after vaccination among HIV-infected adults in Northern Thailand.
METHODS:
A cross-sectional study was conducted in 500 HIV-infected adults aged 20-59 years receiving combination antiretroviral therapy CD4 cell count ≥200 cells/mm(3) and plasma HIV-1 RNA <50 copies/mL and 132 HIV-uninfected controls aged 20-59 years at Chiang Mai University Hospital during July and August 2011. Prevalences of protective antibodies to these viruses as well as serologic responses after MMR vaccination in those without protective antibody to at least one of the three viruses were compared between groups.
RESULTS:
The prevalences of protective antibodies to measles mumps and rubella were 94.2 55.0 and 84.6 % among HIV-infected adults and 97.7 67.5 and 89.4 % among HIV-uninfected controls respectively. The prevalence of protective antibody to mumps was significantly lower in HIV-infected adults (p-value = 0.010). MMR vaccination was done in 249 HIV-infected and 46 HIV-uninfected controls; at week 8 to 12 after vaccination the seroprotective rates against measles mumps and rubella in HIV-infected adults were 96.4 70.7 and 98.0 % respectively whereas those in HIV-uninfected controls were 100 87 and 100 % respectively. No serious adverse effects were observed.
CONCLUSIONS:
In contrast to measles and rubella the prevalence of protective antibody to mumps was low in both HIV-infected adults and HIV-uninfected controls in northern Thailand. The seroprotective rates after MMR vaccination in both groups were considerably high except only for mumps. Therefore MMR vaccination should be considered in all HIV-infected adults receiving antiretroviral therapy with undetectable plasma HIV-1 RNA and CD4 cell count ≥200 cells/mm(3).
TRIAL REGISTRATION:
ClinicalTrials.gov: NCT02724852 registered on March 31 2016.